



Research Paper

Metabolic engineering of *Escherichia coli* for production of valerenadieneS. Eric Nybo^{a,*}, Jacqueline Saunders^a, Sean P. McCormick^b^a Ferris State University, College of Pharmacy, Department of Pharmaceutical Sciences, Big Rapids, MI 49307, USA^b Ferris State University, Department of Physical Sciences, Big Rapids, MI 49307, USA

ARTICLE INFO

Keywords:

Valeriana

Valerenic acid

Metabolic engineering

Sesquiterpene

Escherichia coli

ABSTRACT

Valeriana officinalis is a medicinal herb which produces a suite of compounds in its root tissue useful for treatment of anxiety and insomnia. The sesquiterpene components of the root extract, valerenic acid and valerena-1,10-diene, are thought to contribute to most of the observed anxiolytic of Valerian root preparations. However, valerenic acid and its biosynthetic intermediates are only produced in low quantities in the roots of *V. officinalis*. Thus, in this report, *Escherichia coli* was metabolically engineered to produce substantial quantities of valerena-1,10-diene in shake flask fermentations with decane overlay. Expression of the wildtype valerenadiene synthase gene (pZE-wvds) resulted in production of 12 µg/mL in LB cultures using endogenous FPP metabolism. Expression of a codon-optimized version of the valerenadiene synthase gene (pZE-cvds) resulted in 3-fold higher titers of valerenadiene (32 µg/mL). Co-expression of pZE-cvds with an engineered methyl erythritol phosphate (MEP) pathway improved valerenadiene titers 65-fold to 2.09 mg/L valerenadiene. Optimization of the fermentation medium to include glycerol supplementation enhanced yields by another 5.5-fold (11.0 mg/L valerenadiene). The highest production of valerenadiene resulted from engineering the codon-optimized valerenadiene synthase gene under strong P_{trc} and P_{T7} promoters and via co-expression of an exogenous mevalonate (MVA) pathway. These efforts resulted in an *E. coli* production strain that produced 62.0 mg/L valerenadiene (19.4 mg/L/OD₆₀₀ specific productivity). This *E. coli* production platform will serve as the foundation for the synthesis of novel valerenic acid analogues potentially useful for the treatment of anxiety disorders.

1. Introduction

Valeriana officinalis is a medicinal wild herb indigenous to many habitats, and the root of this plant is used as a nutraceutical preparation (Valerian) that is currently used for the treatment of anxiety and insomnia (Bent et al., 2006). The roots of *V. officinalis* produce a suite of compounds, including valepotriate alkaloids and sesquiterpenes (Bos et al., 1996). Notably, the sesquiterpene components of Valerian root extract are hypothesized to exhibit many of the beneficial anti-anxiety and anti-insomnia effects. Of the sesquiterpenes, valerenic acid is the most potent GABA-A agonist in these extracts, while valeranal, valerenol, and valerena-1,10-diene (valerenadiene) also modulate GABA-A activity to varying extents in zebrafish and mouse models (Del Valle-Mojica and Ortíz, 2012; Takemoto et al., 2014). Most importantly, the anxiolytic effect of valerian has been demonstrated in human clinical studies in recent years (Anderson et al., 2005; Barton et al., 2011).

Valerenic acid in particular has demonstrated nanomolar binding affinity for the GABA-A receptor (Benke et al., 2009). Recently, the putative binding site of valerenic acid has been determined via docking studies and site-directed mutagenesis (Luger et al., 2015). Luger et al.

modeled valerenic acid in the GABA-A receptor in a distinct cleft near the $\beta 2/3N265$ transmembrane residue. The valerenic acid C-12 carboxyl group is predicted to have important hydrogen-bonding interactions with residues $\beta 3N265$ and $\beta 1S265$. Furthermore, the C-13, C-14, and C-15 methyl groups of the valerenane skeleton are predicted to have significant hydrophobic interactions within the pocket at residues within this binding pocket (Fig. 1) (Luger et al., 2015). In summation, these observations have renewed interest in development of novel valerenic acid analogues for structure activity relationship studies.

Despite these advances, valerenic acid is produced as a minor constituent in root tissue of *Valeriana officinalis* (0.7–0.9% DW) (Bos et al., 1998). The low production of valerenic acid hinders further attempts at structure activity relationship and biological activity studies. Synthetic routes toward valerenic acid derivatives are also expensive and ecologically unsuitable. Recently, Ricigliano et al. have engineered *V. officinalis* hairy roots for enhanced production of valerenic acid, which lends credence to a metabolic engineering approach for availing these molecules (Ricigliano et al., 2016). Despite this progress, the hairy root system still produces valerenic acid at very lower titers.

As an alternative approach, metabolic engineering of microbial

* Corresponding author.

E-mail address: EricNybo@ferris.edu (S.E. Nybo).




Fig. 1. Biosynthesis of valerenadiene via the methyl erythritol phosphate pathway (MEP, pathway A) and the mevalonic acid pathway (MVA, pathway B). IPP and DMAPP are synthesized via the MEP or MVA pathways via different upstream routes. The MEP pathway is initiated via condensation of glyceraldehyde 3-phosphate and pyruvate from glycolysis via 1-deoxy-D-xylulose 5-phosphate synthase (DXS), and the MVA pathway is initiated via condensation of two molecules of acetyl-CoA. Two molecules of IPP and one molecule of DMAPP are condensed into C_{15} farnesyl pyrophosphate (FPP). FPP is cyclized into valerenadiene via valerenadiene synthase (VDS). The abbreviations of the enzymes are as follows: DXS, 1-deoxy-D-xylulose 5-phosphate synthase; atoB, thiolase; HMGS, hydroxy-methylglutaryl-CoA synthase; HMGR, truncated hydroxy-methylglutaryl-CoA reductase; ERG12, mevalonate kinase; ERG8, phosphomevalonate kinase; MVD1, diphosphomevalonate decarboxylase; IDI, isopentenyl diphosphate isomerase; FPS, farnesyl pyrophosphate synthase from *Gallus gallus*; IspA, farnesyl pyrophosphate synthase from *Escherichia coli*; VDS, valerenadiene synthase.

organisms represents a green, cost-effective approach for large-scale production of sesquiterpene pharmaceuticals (Zhang et al., 2011). For example, *Escherichia coli* is one such model host that affords several advantages over plant-based systems due to its fast growth kinetics and capacity to produce high-value chemicals via fermentation on simple carbon sources (Lee, 1996). Furthermore, *E. coli* boasts considerable genetic tools, including multiple promoters and expression vectors that establish it as an ideal host for metabolic engineering. Additionally, terpenes are attractive molecules for metabolic engineering, due to their use as fragrances, flavors, and advanced biofuels (Peralta-Yahya et al., 2011; Sowden et al., 2005). Subsequently, these observations established *E. coli* as a suitable platform for engineering of valerenic acid in this present study.

Two specialized isoprenoid biosynthetic pathways exist for production of C_5 isoprenyl phosphate precursors, dimethyl allyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP). Many bacteria, algae, and plant chloroplasts employ the methyl erythritol phosphate pathway (MEP), which fluxes glyceraldehyde-3-phosphate and pyruvate towards IPP and DMAPP (Fig. 1) (Rohmer, 1999). Fungi and non-plant eukaryotes utilize the mevalonate pathway (MVA) to convert acetyl-coenzyme A (acetyl-CoA) to IPP and DMAPP via eight enzymatic steps (Fig. 1) (Martin et al., 2003). Subsequently, IPP and DMAPP are concatenated into progressively longer C_{10} , C_{15} , or C_{20} molecules by prenyltransferase enzymes. For sesquiterpene metabolism, farnesyl pyrophosphate synthase condenses 2 IPP units and 1 DMAPP unit to produce farnesyl pyrophosphate (FPP). Subsequently, FPP can be cyclized by a variety of sesquiterpene hydrocarbons by cognate terpene synthases, such as valerenadiene synthase (VDS) (Fig. 1).

However, *E. coli* generates only a finite pool of FPP, and while introduction of a sesquiterpene synthase results in detectable production of sesquiterpenes (Martin et al., 2001), overproduction of the molecule requires redirecting substantial carbon flux to the limited substrate FPP. For example, amorphadiene is a sesquiterpene intermediate in the biosynthesis of the antimalarial drug artemisinin. Martin and co-workers discovered that heterologous expression of the mevalonate isoprenoid pathway from yeast in *E. coli* leads to unregulated carbon flux towards FPP and amorphadiene, which can be semi-synthetically converted to artemisinin (Martin et al., 2003). In using this substrate-engineering approach, Keasling and co-workers have produced amorphadiene in *E. coli* at yields of 500 mg L^{-1} in shake flask (Redding-Johanson et al., 2011) and 27 g L^{-1} in bioreactors (Tsuruta et al., 2009). This generalized approach lends itself to the microbial synthesis of other sesquiterpenes via introduction of variant terpene synthases. To this end, we extended this metabolic engineering concept to the microbial synthesis of valerenadiene. In this report, we developed a metabolic engineering platform for synthesis of valerenadiene in *E. coli*

using a codon-optimized valerenadiene synthase and engineered MEP and MVA pathways.

2. Methods and materials

2.1. Bacterial strains and growth conditions

E. coli JM109 (New England Biolabs) was used as the host for all routine cloning manipulations, and *E. coli* DH5 α Z1 (Expressys, Germany) and *E. coli* BL21 (DE3) (ThermoFisher) were used as hosts for sesquiterpene production (Supplementary Table 1). *E. coli* DH5 α Z1 overexpresses a copy of the lacI repressor on the chromosome for efficient repression of the lac operator (Lutz and Bujard, 1997). Chemically competent *E. coli* were generated with the *E. coli* Mix and Go Transformation Kit (ZYMO Research) and were transformed using standard molecular methodologies (Sambrook and Russell, 2001). *E. coli* strains were grown in LB agar or LB broth at 37°C for routine maintenance. For production of sesquiterpenes, *E. coli* DH5 α Z1 derivatives were grown in 2xYT with supplemented glycerol at 30°C . For production of valerenadiene. For expression of the mevalonic acid pathway, bacterial growth media was buffered with phosphate buffered saline using a stock solution of $10\times$ PBS (Sambrook and Russell, 2001). Strains were supplemented with ampicillin ($100 \mu\text{g mL}^{-1}$), chloramphenicol ($35 \mu\text{g mL}^{-1}$), and kanamycin ($50 \mu\text{g mL}^{-1}$) as necessary. When multiple plasmids were co-expressed, the chloramphenicol and kanamycin concentrations were adjusted to one-half these amounts.

2.2. Cloning of vds and engineered MEP pathway constructs

Oligonucleotide primers were synthesized by IDT-DNA (Supplementary Table 2), and sequences were verified by sequencing analysis (ACGT, Inc.). Polymerase chain reaction was carried out using PrimeStar[®] HS Polymerase (Takara Bio.) by following the manufacturer's protocols. The wildtype valerenadiene synthase gene (*wvds*) gene was amplified via polymerase chain reaction from the pET28a (+)-VoTPS1 (hereafter referred to as pET-*wvds*) construct as described previously (Yeo et al., 2013). Codon usage analysis and codon optimization services were provided via the GenScript OptimumGene[™] service before performing gene synthesis. The *cvds* gene was codon-optimized for expression in *E. coli*, synthesized, and spliced into cloning vector pUC57-*cvds* (GenScript). The *cvds* gene was amplified via polymerase chain reaction, and both the *wvds* and *cvds* genes were cut and spliced into the *EcoRI/BamHI* restriction sites of pZE12MCS under the control of the intermediate strength P_{lacO1} promoter (Expressys, Germany) to afford constructs pZE-*wvds* and pZE-*cvds*, respectively (Lutz and Bujard, 1997). For insertion under the stronger P_{trc} promoter, *cvds* was PCR

amplified, cut, and spliced into the *Bam*HI/*Eco*RI sites of pTrcHisA (Thermo Fisher Scientific) to afford pTrcHis-*cvds*. In this construct, *cvds* is fused to the N-terminal hexahistidine and Xpress™ epitope tags. For comparisons involving the P_{T7} promoter, the *cvds* gene was cloned into the *Nco*I and *Eco*RI sites of pET28a(+) to afford pET-*cvds*. pET-*wvds* features *wvds* fused to the P_{T7} promoter and was included in experiments to reflect baseline production of valerenadiene from T7-polymerase driven expression of the wildtype gene.

The *dxs-idi-fps* genes were synthesized as a polycistron as previously described in vector pUC57-operon 3 (Genscript) (Bell et al., 2014). The *dxs-idi-fps* genes were digested with *Eco*RI/*Bam*HI and were spliced into the *Eco*RI/*Bam*HI sites of pSTV28 to afford pSTV-*dxs-idi-fps*.

2.3. Cloning and expression of mevalonate pathways

pBbA5c-MevT(CO)-MBIS(CO, *ispA*) was a gift from Jay Keasling & Taek Soon Lee (Addgene plasmid # 35151). For co-expression of valerenadiene synthase and the mevalonate pathway, *E. coli* competent cells were co-transformed with the relevant constructs and plated on LB agar supplemented with antibiotics. For terminal endpoint assays, *E. coli* strains were grown in 1 mL of LB supplemented with antibiotics for 12–16 h until the strains were in stationary phase growth, and then they were inoculated into 5 mL 2 x YT medium containing 3% glycerol with an overlay of 1 mL of decane. For time course assays, *E. coli* strains were grown in 50 mL 2 x YT medium containing 3% glycerol with an overlay of 10 mL of decane. Time points were collected at 12, 24, 36, 48, 72, and 96 h of 100 microliters of culture broth (for OD₆₀₀ measurements) and 100 microliters of decane overlay for valerenadiene determination.

2.4. GC–MS analysis of valerenadiene

Valerenadiene production by the various strains was measured by GC–MS via selective ion monitoring for the molecular ion (204 *m/z*), the 189 *m/z* ion, and the 69 *m/z* ion, as described previously (Martin et al., 2003). Cells were grown in LB or 2 x YT medium with 3% glycerol and induced with 200 micromolar IPTG to express the *wvds* or *cvds* gene and either the engineered MEP operon or the mevalonate pathways. Cultures were covered with a 20% (v/v) decane overlay to trap volatile sesquiterpenes. 100 microliters of decane overlay was diluted in 900 microliters of hexane, and 1 microliter of sample was subjected to GC–MS analysis. Samples were analyzed at the Ferris State University Shimadzu Core Laboratory for Academic Research Excellence (FSU-SCLARE) on a Shimadzu QP-2010 Ultra GC mass spectrometer. Valerenadiene in experimental samples was compared to authentic valerenadiene standard. Valerenadiene concentration was converted to beta caryophyllene equivalents using a caryophyllene standard curve and the relative abundance of 69 *m/z*, 189 *m/z*, and 204 *m/z* mass fragments. Valerenadiene standard was isolated as described previously (Yeo et al., 2013).

3. Results and discussion

3.1. Valerenadiene production in *E. coli* and gene optimization

Previously, other groups have reported that sesquiterpene production in *E. coli* is limited by poor expression of cognate plant terpene synthases (Martin et al., 2001; Wang et al., 2011). We surmised that the *wvds* gene may encode several rare codons that inhibit optimal translation in *E. coli*. First, we analyzed the codon usage of the wildtype valerenadiene synthase gene (VoTPS2, Accession No. J9R5V4.1)¹ from *Valeriana officinalis* to determine rare codons that could hinder

expression in *E. coli* (Pyle et al., 2012). This analysis was conducted before synthesizing a codon-optimized version of valerenadiene synthase gene (*cvds*) (GenScript). The analysis revealed that the *wvds* gene exhibited a codon-adaptation index (CAI) of 0.59 (Sharp and Li, 1987), which indicates the potential for poor gene expression in *E. coli* due to the presence of 16 rare codons (e.g. defined as usage frequency in *Escherichia coli* < 30%) (GenScript). In this analysis, a CAI of > 0.8 is considered good and is predicted to correlate with high gene expression in the chosen organism. Second, we synthesized a codon-optimized *cvds* gene (*cvds*) without internal *Xba*I, *Spe*I, *Eco*RI, and *Nde*I restriction sites to facilitate cloning. The refactored *cvds* gene exhibited a CAI of 0.89 and featured no rare codons. Third, we incorporated strong 5'-AAGG-AGGT ribosome binding sites (RBS) upstream of the start codon for *wvds* and *cvds*. However, one limitation of this study is that further optimization of the RBS was not attempted. Optimization of the RBS can result in enhanced protein translation, which can further augment metabolic flux down a pathway. For example, Nowroozi et al. improved amorphaadiene production titers in *E. coli* by altering the RBS for amorphaadiene synthase and several upstream MVA pathway genes (Nowroozi et al., 2014).

Our cloning strategy utilized two different sets of vectors with compatible replicons. First, throughout the study, the *wvds/cvds* genes were cloned into high-copy number colE1-based vectors (i.e. approximately 70–100 plasmid copies per cell). This strategy was maintained as we cloned *wvds/cvds* downstream of strong promoters in colE1-based plasmids, pZE12MCS, pTrcHisA, and pET28a(+). Second, engineered MEP or MVA pathway constructs were cloned into intermediate-copy number p15A-based vectors (i.e. approximately 30–50 plasmid copies per cell). Initially, the *wvds/cvds* genes were cloned into colE1-based pZE12MCS under the control of the IPTG-inducible P_{LlacO1} promoter (Lutz and Bujard, 1997). This afforded the constructs pZE-*wvds*, pZE-*cvds*, and pZE12MCS.

pZE-*wvds*, pZE-*cvds*, and empty pZE12MCS vector were transformed in *E. coli*. The *E. coli* lines were grown in 5 mL of LB medium supplemented with ampicillin. The cultures were overlaid with 1 mL decane for 48 h and induced with IPTG. A major valerenadiene peak was detected in extracts of pZE-*wvds* and pZE-*cvds* cultures that eluted at the same retention time and exhibited identical mass fragmentation pattern to valerenadiene standard (Supplementary Fig. 1). This peak was not detected in pZE12MCS control strains, which confirmed low production of valerenadiene in the VDS-engineered lines. *E. coli* pZE-*wvds* produced 8 µg/L and 12 µg/L valerenadiene at 24 and 48 h, respectively, whereas *E. coli* pZE-*cvds* produced 16 and 32 µg/L valerenadiene at 24 and 48 h, respectively (Fig. 2). These results suggest that the codon-optimized valerenadiene synthase is more efficiently expressed than the wildtype version, which results in a 3-fold improvement in valerenadiene titer. The strains grew to similar culture densities.

However, the yields of valerenadiene achieved were quite low, and we surmised this was likely due to low levels of prenyl phosphate precursors (IPP, DMAPP, and FPP). The endogenous MEP pathway of *E. coli* produces a small pool of FPP that is the precursor for *trans*-octaprenyl diphosphate (ODP) in production of ubiquinone and *cis*,-undecaprenyl *trans*-undecaprenyl diphosphate (UDP) for production of peptidoglycan (Asai et al., 1994; Bouhss et al., 2008; Okada et al., 1997). However, the production of FPP by the endogenous pathway is limited due to regulation of several key steps (Estévez et al., 2001). Therefore, we designed a construct that would overexpress rate-limiting steps of the MEP pathway to augment greater carbon flux from primary metabolism to FPP. In our previous work, we engineered *Rhodobacter capsulatus* to produce high levels of the triterpene botryococcene, which is biosynthesized from two molecules of FPP via squalene synthase-like enzymes (SSL-1 and SSL-3), via expression of the deoxy-xylulose phosphate synthase (*dxs*), isopentenyl diphosphate isomerase (*idi*) genes from *E. coli*, and farnesyl pyrophosphate synthase (*fps*) gene from *Gallus gallus* (Khan et al., 2015). Fusion of the *dxs-idi-fps* genes to the SSL-1 + 3 chimeric botryococcene synthase and expression of the

¹ The gene *vtps2* henceforth is referred to as *wvds* (wildtype valerenadiene synthase) to distinguish it from *cvds* (codon-optimized valerenadiene synthase).




Fig. 2. Engineering of wildtype (pZE-wvds) and codon-optimized (pZE-cvds) valerenadiene synthase. (A) *E. coli* engineered with empty vector control, wildtype, and codon optimized VDS genes was grown for 24 (open bars) and 48 h (filled bars) and yield of valerenadiene was determined. (B) Growth of engineered *E. coli* lines was determined by measuring optical density (OD₆₀₀) at 24 (open bars) and 48 h (filled bars), respectively. (C) *E. coli* strains were co-transformed with empty vector control, wvds, cvds, and pSTV-dxs-idi-fps for enhancement of the endogenous MEP pathway. (D) Growth of engineered *E. coli* lines was determined by measuring optical density (OD₆₀₀). Strains were inoculated in 5 mL cultures of LB media with 1 mL decane overlay and experiments were carried out in triplicate. Error bars indicate standard error of the mean.

resulting construct generated 5 mg/gDW production of botryococcene in the *R. capsulatus* host. In a similar fashion, we fused the *dxs-idi-fps* genes under the control of the IPTG-inducible P_{lacUV5} promoter of pSTV28 to generate construct pSTV-dxs-idi-fps. This construct was co-transformed with pZE-wvds and pZE-cvds, and the lines were grown in 5 mL LB medium with decane overlay at 30 °C for 48 h and induced with IPTG. Co-expression of pSTV-dxs-idi-fps with pZE-wvds and pZE-cvds resulted in a 14-fold increase (0.17 mg/L) and a 65-fold increase (2.09 mg/L) in production of valerenadiene, respectively (Fig. 2). The engineered lines grew to a lower density than the pZE12MCS control, indicating significant metabolic burden from the engineered MEP pathway. Furthermore, the pSTV-dxs-idi-fps/pZE-cvds strain grew better than the pSTV-dxs-idi-fps/pZE-wvds strain after 24 h but decreased after 48 h. This result was reproducible after repeating the experiment on two different days. One possible explanation is that expression of the pZE-cvds construct results in more efficient translation of valerenadiene synthase than pZE-wvds, which results in more efficient coupling of FPP to valerenadiene. Martin et al. demonstrated previously that accumulation of IPP/DMAPP and FPP leads to growth inhibition in engineered *E. coli* lines (Martin et al., 2003). These results demonstrate that expression of the engineered MEP pathway greatly augmented carbon flux to FPP and valerenadiene.

3.2. Effect of glycerol supplementation on valerenadiene production

With the engineered MEP pathway construct in hand, we hypothesized that optimization of the production medium could further enhance sesquiterpene yield. In fact, Zhang et al. reported that glycerol supplementation of culture medium increased sabinene production to > 40 mg/L in *E. coli* engineered with sabinene synthase and a heterologous mevalonate pathway (Zhang et al., 2014). Furthermore, Morrone and co-workers engineered higher levels of C₂₀ abietadiene production and increased biomass when glycerol supplemented media was used (e.g. increasing abietadiene specific productivity from 1 mg/L/OD₆₀₀ without glycerol supplementation to 2.5 mg/L/OD₆₀₀ with

glycerol supplementation) (Morrone et al., 2010). *E. coli* pZE-wvds/pSTV-dxs-idi-fps and *E. coli* pZE-cvds/pSTV-dxs-idi-fps were grown in 5 mL of 2 x YT medium supplemented with 0–5% glycerol. The *E. coli* pZE-wvds/pSTV-dxs-idi-fps valerenadiene production increased 15-fold from 0.11 mg/L to 1.5 mg/L when supplemented with glycerol, however, further production was possibly limited by poor heterologous expression of valerenadiene synthase. In contrast, *E. coli* pZE-cvds/pSTV-dxs-idi-fps demonstrated better responsiveness to the glycerol supplementation, as valerenadiene productivity increased from 5.1 mg/L to 11.0 mg/L when supplemented with 3% glycerol (Fig. 3).




Fig. 3. Effect of glycerol conditions on production of valerenadiene. *E. coli* strains engineered with pZE-wvds and pSTV-dxs-idi-fps or pZE-cvds and pSTV-dxs-idi-fps were grown in 5 mL 2xYT media with 0%–4% glycerol and 1 mL decane overlay for 48 h and valerenadiene yield was determined. Experiments were carried out in triplicate and error bars indicate standard error of the mean.




Fig. 4. Time course of *E. coli* expressing an engineered MEP pathway and valerenadiene synthase. *E. coli* DH5 α Z1 strains harboring the engineered MEP construct pSTV-*dxs-idi-fps* were co-expressed with pZE-*wvds* or pZE-*cvds*. Cultures were grown in 50 mL 2 x YT + 3% glycerol with 10 mL decane overlay for 72 h. Valerenadiene yield (mg/L, solid lines) and culture growth (OD₆₀₀, dotted lines) were determined from double triplicate experiments. Error bars indicate the standard error of the mean.

Therefore, 3% glycerol was used for all further experiments.

To observe production of valerenadiene over time, we conducted a time course of *E. coli* pZE-*wvds*/pSTV-*dxs-idi-fps* and *E. coli* pZE-*cvds*/pSTV-*dxs-idi-fps* in 2 x YT + 3% glycerol media over 72 h. The results of the time course replicated the observations in the glycerol supplementation experiment. *E. coli* co-expressing the engineered MEP pathway and the *wvds* gene reached maximal growth (OD₆₀₀ = 9.0) and valerenadiene production (3 mg/L) at 24 h (Fig. 4). The *E. coli* line co-expressing the engineered MEP pathway and *cvds* gene reached also reached both its greatest level of growth (OD₆₀₀ = 9.0) and valerenadiene production (10.6 mg/L) at 24 h. Valerenadiene concentration decreased in both lines from 48 to 72 h, likely due to volatilization of the sesquiterpene.

3.3. Engineering of *vds* under the *P_{trc}* promoter

We hypothesized that low-level expression of the terpene synthase from the *P_{LacO1}* promoter might be a metabolic rate-limiting factor in the turnover of FPP substrate. Based on the previous experiment, expression of the *cvds* gene resulted in 5–10-fold higher quantities of valerenadiene than expression of *wvds*, depending on glycerol supplementation, which was inferred to be the direct result of higher concentration of terpene synthase catalyst in the *E. coli* cell. Therefore, the *cvds* gene was fused to the strong *P_{trc}* promoter to afford construct pTrcHis-*cvds*. This construct was expressed alone and co-expressed with pSTV-*dxs-idi-fps* in *E. coli* DH5 α Z1 cells in triplicate 5 mL 2xYT + 3% glycerol fermentations for 48 h. The strain harboring pTrcHis-*cvds* produced 0.046 mg/L valerenadiene, whereas the strain harboring pTrcHis-*cvds* and pSTV-*dxs-idi-fps* produced approximately 20.3 mg/L (Supplementary Fig. 2). This represents a 440-fold improvement over the pTrcHis-*cvds* only expression line. Furthermore, expression of the *cvds* gene by the *P_{trc}* promoter (e.g. by strain *E. coli* DH5 α Z1/(pTrcHis-*cvds*)/(pSTV-*dxs-idi-fps*)) represented a 40% increase in valerenadiene titers as compared to expression from *P_{LacO1}* (e.g. by strain *E. coli* DH5 α Z1/(pZE-*cvds*)/(pSTV-*dxs-idi-fps*)).

Recently, the MEP pathway has been demonstrated to be subject to endogenous regulation by *E. coli*, possibly due to feedback inhibition of the metabolite methylerythritol cyclodiphosphate (MEcDP) (Banerjee and Sharkey, 2014). We rationalized that FPP enhancement might be limited via the MEP pathway, therefore we co-expressed an exogenous MVA pathway to greatly augment FPP precursor levels along with pTrcHis-*cvds*. In a previous study, Peralta-Yahya and co-workers engineered a heterologous MVA pathway for production of the sesquiterpene biofuel bisabolene (Peralta-Yahya et al., 2011). Expression of




Fig. 5. Time course experiment of *E. coli* co-expressing pTrcHis-*cvds* and the *Saccharomyces cerevisiae* MVA pathway. *E. coli* DH5 α Z1 strains harboring the pBbA5c-MevT + MBIS(CO,ispA) and pTrcHis-*cvds* constructs were grown in 50 mL 2 x YT + 3% glycerol with 10 mL decane overlay for 72 h. Valerenadiene yield (mg/L, solid line) and culture growth (OD₆₀₀, dotted line) were determined from double triplicate experiments. Error bars indicate the standard error of the mean.

the construct pBbA5c-MevT(CO)-MBIS(CO, ispA) along with the codon-optimized AgBis gene resulted in production of 586 ± 65 mg/L bisabolene. pBbA5c-MevT(CO)-MBIS(CO, ispA) features a codon-optimized, eight gene MVA pathway driven by the *P_{trc}* promoter on a medium copy number plasmid (Supplementary Table 1). The three upstream gene products (*atoB*, *hmgS*, *thmGr*) convert acetyl-CoA to mevalonic acid, and the five downstream gene products (*erg12*, *erg8*, *mvd1*, *idi*, *ispA*) convert mevalonic acid to farnesyl pyrophosphate (Fig. 1). Similarly, *E. coli* DH5 α Z1 was transformed with pTrcHis-*cvds* and pBbA5c-MevT(CO)-MBIS(CO, ispA) and grown in triplicate 5 mL 2xYT + 3% glycerol fermentations for 48 h. This strain produced 42.5 mg/L valerenadiene, a 1000-fold increase over the *cvds*-expressing line and a 2-fold increase over the engineered MEP pathway (Supplementary Fig. 2). This result demonstrated that the mevalonic acid pathway efficiently coupled the microbial synthesis of FPP to valerenadiene synthase to produce significant levels of valerenadiene. Thus, the mevalonic acid pathway was used for further experiments. These results were further confirmed in a time course experiment of the same strain, which achieved a titer of 35 mg/L valerenadiene at 24 h (Fig. 5).

3.4. Co-expression of *vds* with the T7 RNA polymerase promoter and MVA pathway

We observed that the *P_{trc}*-*cvds* gene constructs demonstrated more robust production of valerenadiene than the comparatively weaker *P_{LacO1}*-*cvds* gene constructs, and we inferred that levels of VDS catalyst may be rate-limiting in this latter system. Therefore, we decided to compare the expression of the *wvds* and *cvds* genes from a “weak” promoter system (*P_{LacO1}*), an “intermediate/strong” promoter system (*P_{trc}*), and a strong promoter system (*P_{T7}*) along with the mevalonic acid pathway. We hypothesized that the *P_{LacO1}* promoter might not be able to drive sufficient expression of VDS to efficiently turnover the abundant FPP substrate synthesized via the mevalonic acid pathway. *E. coli* DH5 α Z1 pZE-*wvds* and *E. coli* DH5 α Z1 pZE-*cvds* were grown in triplicate cultures as before and produced minimal amounts of valerenadiene (Supplementary Fig. 3). When pBbA5c-MevT(CO)-MBIS(CO, ispA) was co-expressed in these lines, they produced 2.8 mg/L (0.497 mg/L/OD₆₀₀) and 7.3 mg/L (1.03 mg/L/OD₆₀₀), respectively, which strongly suggested that the amount of VDS catalyst was limited (Supplementary Fig. 3). Expression of *cvds* from the *P_{trc}* promoter with the mevalonic acid pathway increased production 6-fold to 42.5 mg/L (6.07 mg/L/OD₆₀₀) (Supplementary Fig. 3).

Subsequently, the *wvds* and *cvds* genes were cloned into pET28a for expression under the strong T7 RNA polymerase promoter. The




Fig. 6. Production of valerenadiene using the T7 RNA polymerase to drive expression of *vds*. *E. coli* BL21(DE3) strains harboring empty vector control, pET-wvds, and pET-cvds were expressed with and without the *Saccharomyces cerevisiae* MVA pathway (pBBa5c-MevT-MBIS(CO, IspA)). Strains were grown in triplicate 2xYT media + 3% glycerol fermentations with 1 mL decane overlay for 48 h. Valerenadiene volumetric production (mg/L) and specific productivity (mg/L/OD₆₀₀) were determined after 48 h.

resulting constructs, pET-wvds and pET-cvds were introduced into *E. coli* BL21(DE3) cells to utilize the IPTG-inducible T7 RNA polymerase system. These plasmids were transformed alone or in combination with the mevalonic acid pathway and grown in triplicate 2xYT + 3% glycerol cultures for 48 h. The pET-wvds-only line produced 0.345 mg/L valerenadiene, whereas the pET-cvds-only line produced 1.09 mg/L valerenadiene (Fig. 6). Co-expression of pET-wvds and pBBa5c-MevT(CO)-MBIS(CO, ispA) resulted in production of 10.5 mg/L valerenadiene (3.27 mg/L/OD₆₀₀) (Fig. 6). Most importantly, when pET-cvds was introduced with the mevalonic acid pathway, the highest-yielding valerenadiene strain was achieved with production of 62.0 mg/L valerenadiene (19.4 mg/L/OD₆₀₀ specific productivity). These experiments demonstrated that the amount of VDS catalyst and FPP substrate *in vivo* are both limiting factors for production of valerenadiene, which can be remedied via expression of *cvds* from a strong P_{trc}/P₁₇ promoter and heterologous expression of the mevalonic acid pathway.

4. Conclusions

In this study, we engineered a codon-optimized version of the valerenadiene synthase gene (*cvds*) and compared it alongside the wild-type gene (*wvds*). The *cvds* gene resulted in more robust strain growth and 3-fold higher production of valerenadiene. This very likely indicates that translation of the codon-optimized form of the gene is very efficient. Further improvements in productivity were realized by the overexpression of an engineered MEP pathway composed of the *dxs*, *idi*, and *fps* genes. This strategy resulted in 65-fold increase in production of valerenadiene (2.09 mg/L). This was improved a further 6-fold by optimizing the fermentation medium to 2xYT with 3% glycerol supplementation (11.0 mg/L). Next, the *cvds* gene was fused to the stronger P_{trc} promoter, which resulted in approximately 40% increase in production of valerenadiene when pTrcHis-*cvds* was co-expressed with the engineered MEP pathway (20 mg/L). This result demonstrated the importance of driving expression of valerenadiene synthase from strong promoters to ensure ample availability of terpene synthase catalyst. However, the greatest increases in valerenadiene yield involved heterologous expression of the *Saccharomyces cerevisiae* mevalonic acid

pathway. Expression of the MVA pathway resulted in an unregulated metabolic flux towards FPP, which could be efficiently coupled to valerenadiene synthase for production of 62.0 mg/L valerenadiene in culture tubes with a specific productivity of 19.4 mg/L/OD₆₀₀. This study showed that *E. coli* is capable of high-level production of valerenadiene with relatively minimal optimization of the production media and commercially available expression vectors, such as pBBa5c-MevT-MBIS(CO,IspA). Further efforts to improve this *E. coli* platform will involve balancing of the MVA pathway, development of rational CYP450 candidates to oxygenate valerenadiene, and scale-up of optimized producing lines in a bioreactor.

Funding

S.E.N. was supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation and a Faculty Research Grant from Ferris State University. J.S. was supported by a Summer Research Fellowship from Ferris State University. S.P.M. was supported by a Faculty Research Grant and Ferris Merit Foundation Grant from Ferris State University.

Acknowledgements

The authors gratefully acknowledge Scott Kinison, Garrett Zinck, and Dr. Joseph Chappell (University of Kentucky) for the pET-wvds and cloning of the pET-cvds constructs, valerenadiene standard, and helpful discussions concerning GC–MS protocols. The Ferris State University Shimadzu Core Laboratory for Academic and Research Excellence (SCLARE) is gratefully acknowledged for GC–MS analysis.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.jbiotec.2017.10.004>.

References

- Anderson, G.D., Elmer, G.W., Kantor, E.D., Templeton, I.E., Vitiello, M.V., 2005. Pharmacokinetics of valerianic acid after administration of valerian in healthy subjects. *Phyther. Res.* 19, 801–803. <http://dx.doi.org/10.1002/ptr.1742>.
- Asai, K., et al., 1994. The identification of *Escherichia coli* ispB (cel) gene encoding the octaprenyl diphosphate synthase. *Biochem. Biophys. Res. Commun.* 202, 340–345.
- Banerjee, A., Sharkey, T.D., 2014. Methylerythritol 4-phosphate (MEP) pathway metabolic regulation. *Nat. Prod. Rep.* 31, 1043–1055. <http://dx.doi.org/10.1039/c3np70124g>.
- Barton, D.L., Atherton, P.J., Bauer, B.A., Moore, D.F., Mattar, B.I., LaVasseur, B.I., Rowland, K.M., Zon, R.T., LeLindqwister, N.A., Nagargoje, G.G., Morgenthaler, T.L., Sloan, J.A., Loprinzi, C.L., 2011. The use of *Valeriana officinalis* (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG trial, N01C5). *J. Support Oncol.* 9, 24–31. <http://dx.doi.org/10.1016/j.suponc.2010.12.008>.
- Bell, S.A., Niehaus, T.D., Nybo, S.E., Chappell, J., 2014. Structure-function mapping of key determinants for hydrocarbon biosynthesis by squalene and squalene synthase-like enzymes from the green alga *Botryococcus braunii* race B. *Biochemistry* 53, 7570–7581. <http://dx.doi.org/10.1021/bi501264s>.
- Benke, D., Barberis, A., Kopp, S., Altmann, K.H., Schubiger, M., Vogt, K.E., Rudolph, U., Muhler, H., 2009. GABAA receptors as *in vivo* substrate for the anxiolytic action of valerianic acid, a major constituent of valerian root extracts. *Neuropharmacology* 56, 174–181. <http://dx.doi.org/10.1016/j.neuropharm.2008.06.013>.
- Bent, S., Padula, A., Moore, D., Patterson, M., Mehling, W., 2006. Valerian for sleep: a systematic review and meta-analysis. *Am. J. Med.* <http://dx.doi.org/10.1016/j.amjmed.2006.02.026>.
- Bos, R., Woerdenbag, H.J., Hendriks, H., Zwaving, J.H., De Smet, P.A.G.M., Tittel, G., Wikstrom, H.V., Scheffer, J.J.C., 1996. Analytical aspects of phytotherapeutic valerian preparations. *Phytochem. Anal.* 7, 143–151. [http://dx.doi.org/10.1002/\(SICI\)1099-1565\(199605\)7:3<143::AID-PCA284>3.0.CO;2-1](http://dx.doi.org/10.1002/(SICI)1099-1565(199605)7:3<143::AID-PCA284>3.0.CO;2-1).
- Bos, R., Woerdenbag, H.J., van Putten, F.M., Hendriks, H., Scheffer, J.J., 1998. Seasonal variation of the essential oil, valerenic acid and derivatives, and velopatriates in *Valeriana officinalis* roots and rhizomes, and the selection of plants suitable for phytomedicines. *Planta Med.* 64, 143–147. <http://dx.doi.org/10.1055/s-2006-957392>.
- Bouhss, A., et al., 2008. The biosynthesis of peptidoglycan lipid-linked intermediates. *FEMS Microbiol. Rev.* 32, 208–233.
- Del Valle-Mojica, L., Ortiz, J., 2012. Anxiolytic properties of valerian *officinalis* in the

- zebrafish: a possible role for metabotropic glutamate receptors. *Planta Med.* 78, 1719–1724. <http://dx.doi.org/10.1055/s-0032-1315240>.
- Estévez, J.M., Cantero, A., Reindl, A., Reichler, S., León, P., 2001. 1-Deoxy-D-xylulose-5-phosphate synthase, a limiting enzyme for plastidic isoprenoid biosynthesis in plants. *J. Biol. Chem.* 276, 22901–22909. <http://dx.doi.org/10.1074/jbc.M100854200>.
- Khan, N., Nybo, S.E., Chappell, J., Curtis, W.R., 2015. Triterpene hydrocarbon production engineered into a metabolically versatile host – *Rhodobacter capsulatus*. *Biotechnol. Bioeng.* <http://dx.doi.org/10.1002/bit.25573>.
- Lee, S.Y., 1996. High cell-density culture of *Escherichia coli*. *Trends Biotechnol.* 14, 98–105. [http://dx.doi.org/10.1016/0167-7799\(96\)80930-9](http://dx.doi.org/10.1016/0167-7799(96)80930-9).
- Luger, D., Poli, G., Wiedner, M., Stadler, M., Ke, S., Ernst, M., Hohaus, A., Linder, T., Seidel, T., Langer, T., Khom, S., Hering, S., 2015. Identification of the putative binding pocket of valerenic acid on GABA_A receptors using docking studies and site-directed mutagenesis. *Br. J. Pharmacol.* 172, 5403–5413. <http://dx.doi.org/10.1111/bph.13329>.
- Lutz, R., Bujard, H., 1997. Independent and tight regulation of transcriptional units in *Escherichia coli* via the LacR/O, the TetR/O and AraC/11-12 regulatory elements. *Nucleic Acids Res.* 25, 1203–1210. <http://dx.doi.org/10.1093/nar/25.6.1203>.
- Martin, V.J.J., Yoshikuni, Y., Keasling, J.D., 2001. The in vivo synthesis of plant sesquiterpenes by *Escherichia coli*. *Biotechnol. Bioeng.* 75, 497–503. <http://dx.doi.org/10.1002/bit.10037>.
- Martin, V.J.J., Pitera, D.J., Withers, S.T., Newman, J.D., Keasling, J.D., 2003. Engineering a mevalonate pathway in *Escherichia coli* for production of terpenoids. *Nat. Biotechnol.* 21, 796–802. <http://dx.doi.org/10.1038/nbt833>.
- Morrone, D., Lowry, L., Determan, M.K., Hershey, D.M., Xu, M., Peters, R.J., 2010. Increasing diterpene yield with a modular metabolic engineering system in *E. coli*: comparison of MEV and MEP isoprenoid precursor pathway engineering. *Appl. Microbiol. Biotechnol.* 85, 1893–1906. <http://dx.doi.org/10.1007/s00253-009-2219-x>.
- Nowroozi, F.F., Baidoo, E.E.K., Ermakov, S., Redding-Johanson, A.M., Batth, T.S., Petzold, C.J., Keasling, J.D., 2014. Metabolic pathway optimization using ribosome binding site variants and combinatorial gene assembly. *Appl. Microbiol. Biotechnol.* 98, 1567–1581. <http://dx.doi.org/10.1007/s00253-013-5361-4>.
- Okada, K., et al., 1997. The *ispB* gene encoding octaprenyl diphosphate synthase is essential for growth of *Escherichia coli*. *J. Bacteriol.* 179, 3058–3060.
- Peralta-Yahya, P.P., Ouellet, M., Chan, R., Mukhopadhyay, A., Keasling, J.D., Lee, T.S., 2011. Identification and microbial production of a terpene-based advanced biofuel. *Nat. Commun.* <http://dx.doi.org/10.1038/ncomms1494>.
- Pyle, B.W., Tran, H.T., Pickel, B., Haslam, T.M., Gao, Z., MacNevin, G., Vederas, J.C., Kim, S.U., Ro, D.K., 2012. Enzymatic synthesis of valeren-4,7(11)-diene by a unique sesquiterpene synthase from the valerian plant (*Valeriana officinalis*). *FEBS J.* 279, 3136–3146. <http://dx.doi.org/10.1111/j.1742-4658.2012.08692.x>.
- Redding-Johanson, A.M., Batth, T.S., Chan, R., Krupa, R., Szmidt, H.L., Adams, P.D., Keasling, J.D., Soon Lee, T., Mukhopadhyay, A., Petzold, C.J., 2011. Targeted proteomics for metabolic pathway optimization: application to terpene production. *Metab. Eng.* 13, 194–203. <http://dx.doi.org/10.1016/j.ymben.2010.12.005>.
- Ricigliano, V., Kumar, S., Kinison, S., Brooks, C., Nybo, S.E.E., Chappell, J., Howarth, D.G.D.G., 2016. Regulation of sesquiterpenoid metabolism in recombinant and elicited *Valeriana officinalis* hairy roots. *Phytochemistry* 125, 43–53. <http://dx.doi.org/10.1016/j.phytochem.2016.02.011>.
- Rohmer, M., 1999. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria(,) algae and higher plants[dagger]. *Nat. Prod. Rep.* 16, 565–574. <http://dx.doi.org/10.1039/A709175C>.
- Sambrook, J., Russell, D.W., 2001. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harb. Lab. Press, Cold Spring Harb. NY, pp. 999.
- Sharp, P.M., Li, W.-H., 1987. The codon adaptation index—a measure of directional synonymous codon usage bias, and its potential applications. *Nucleic Acids Res.* 15, 1281–1295. <http://dx.doi.org/10.1093/nar/15.3.1281>.
- Sowden, R.J., Yasmin, S., Rees, N.H., Bell, S.G., Wong, L.-L., 2005. Biotransformation of the sesquiterpene (+)-valencene by cytochrome P450cam and P450BM-3. *Org. Biomol. Chem.* 3, 57–64. <http://dx.doi.org/10.1039/b413068e>.
- Takemoto, H., Omameuda, Y., Ito, M., Fukuda, T., Kaneko, S., Akaike, A., Kobayashi, Y., 2014. Inhalation administration of valeren-4,7(11)-diene from *nardostachys chinensis* roots ameliorates restraint stress-induced changes in murine behavior and stress-related factors. *Biol. Pharm. Bull.* 37, 1050–1055. <http://dx.doi.org/10.1248/bpb.b14-00136>.
- Tsuruta, H., Paddon, C.J., Eng, D., Lenihan, J.R., Horning, T., Anthony, L.C., Regentin, R., Keasling, J.D., Renninger, N.S., Newman, J.D., 2009. High-level production of amorpha-4, 11-diene, a precursor of the antimalarial agent artemisinin, in *Escherichia coli*. *PLoS One* 4. <http://dx.doi.org/10.1371/journal.pone.0004489>.
- Wang, C., Yoon, S.-H., Jang, H.-J., Chung, Y.-R., Kim, J.-Y., Choi, E.-S., Kim, S.-W., 2011. Metabolic engineering of *Escherichia coli* for α -farnesene production. *Metab. Eng.* 13, 648–655. <http://dx.doi.org/10.1016/j.ymben.2011.08.001>.
- Yeo, Y.-S., Nybo, S.E., Chittiboyina, A.G., Weerasooriya, A.D., Wang, Y.-H., Góngora-Castillo, E., Vaillancourt, B., Buell, C.R., DellaPenna, D., Celiz, M.D., Jones, A.D., Wurtele, E.S., Ransom, N., Dudareva, N., Shaaban, K.A., Tibrewal, N., Chandra, S., Smillie, T., Khan, I.A., Coates, R.M., Watt, D.S., Chappell, J., 2013. Functional identification of valeren-1,10-diene synthase, a terpene synthase catalyzing a unique chemical cascade in the biosynthesis of biologically active sesquiterpenes in *Valeriana officinalis*. *J. Biol. Chem.* 288, 3163–3173. <http://dx.doi.org/10.1074/jbc.M112.415836>.
- Zhang, F., Rodriguez, S., Keasling, J.D., 2011. Metabolic engineering of microbial pathways for advanced biofuels production. *Curr. Opin. Biotechnol.* 22, 775–783. <http://dx.doi.org/10.1016/j.copbio.2011.04.024>.
- Zhang, H., Liu, Q., Cao, Y., Feng, X., Zheng, Y., Zou, H., Liu, H., Yang, J., Xian, M., 2014. Microbial production of sabinene—a new terpene-based precursor of advanced biofuel. *Microb. Cell Fact.* 13, 20. <http://dx.doi.org/10.1186/1475-2859-13-20>.